Article

Autoantibodies Appear Early in Sjögren Syndrome

A quintet of autoantibodies seem to turn up nearly two decades before symptom onset in primary Sjögren Syndrome. Also, yet more on bacteria as triggers of RA.

Last week's articles on rheumatology topics in the major non-rheumatology journals.Autoantibodies Present Before Symptom Onset in Primary Sjgren SyndromeJAMA, November 6, 2013

Patients with primary Sjgren Syndrome (pSS) had autoantibodies long before symptoms appeared. 

Since 1984, 360 patients have been diagnosed with pSS at Malm hospital in Sweden. Among the 44 of these patients who previously contributed serum samples to a biobank for unrelated reasons, 29 (66%) had detectible autoantibodies in their earliest serum samples – as early as 18 years before symptom onset.

The antibodies were antinuclear antibodies, rheumatoid factor, anti-Ro60/SSA, anti-Ro52/SSA, and anti-La/SSB.

 

Editorial: Idiopathic pulmonary fibrosisBMJ, November 7, 2013

Idiopathic pulmonary fibrosis - pirfenidone (TA282)
NICE Technology appraisals, April 2013

The UK's National Institute for Health and Care Excellence (NICE) has approved pirfenidone for mild to moderate idiopathic pulmonary fibrosis, which can co-occur with rheumatoid arthritis.

A Cochrane review found that pirfenidone reduces the risk of disease progression by 30%, although it has no effect on mortality. The orally administered drug is antifibrotic, anti-inflammatory, and antioxidant.
Pirfenidone is available in Europe, but not in the US, where a phase III trial for approval is underway.



Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritiseLife, November 5, 2013

The intestinal bacterium Prevotella corpri (P. corpri) was found in the intestines of 75% of patients with newly diagnosed rheumatoid arthritis (RA), but in only 37% of patients with psoriatic arthritis or established RA compared with 21% of healthy controls.

Researchers sequenced the 16S ribosomal RNA, which is used to identify bacteria, from the stool samples of 114 patients and controls.

In mouse models, P. corpri displaces normal Bacteroides species, activates Th17 cells, and causes inflammation.

However, these results don’t demonstrate that P. corpri causes RA in humans. RA may favor the growth of P. corpri, or a third factor may promote RA and P. corpri.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.